









Markets
/
Stocks
/
nasdaq-ctnm
/

Contineum Therapeutics Inc

CTNM

15.000USD

+0.520+3.59%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

437.74MMarket Cap

LossP/E TTM



Contineum Therapeutics Inc

15.000

+0.520+3.59%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Contineum Therapeutics Inc

Currency: USD Updated: 2026-02-05

Key Insights

Contineum Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 16 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.33.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Contineum Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

16 / 392

Overall Ranking

107 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Contineum Therapeutics Inc Highlights

StrengthsRisks

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -6.42, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 17.77M shares, increasing 0.03% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 1.29K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

20.333

Target Price

+41.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-05

The current financial score of Contineum Therapeutics Inc is 8.66, ranking 38 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.66

Change



Financials

8.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.62

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Contineum Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-05

The current valuation score of Contineum Therapeutics Inc is 6.70, ranking 236 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.42, which is -525.54% below the recent high of 27.33 and -174.16% above the recent low of -17.61.

Score

Industry at a Glance

Previous score

6.70

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 16/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-05

The current earnings forecast score of Contineum Therapeutics Inc is 8.86, ranking 43 out of 392 in the Biotechnology & Medical Research industry. The average price target is 22.00, with a high of 29.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.86

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

20.333

Target Price

+40.42%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Contineum Therapeutics Inc

CTNM

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-05

The current price momentum score of Contineum Therapeutics Inc is 9.25, ranking 8 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 17.11 and the support level at 10.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.34

Change

-0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.385

Buy

RSI(14)

68.330

Neutral

STOCH(KDJ)(9,3,3)

77.803

Neutral

ATR(14)

1.080

High Vlolatility

CCI(14)

81.053

Neutral

Williams %R

10.714

Overbought

TRIX(12,20)

1.312

Sell

StochRSI(14)

34.018

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

14.774

Buy

MA10

14.419

Buy

MA20

12.929

Buy

MA50

11.992

Buy

MA100

11.667

Buy

MA200

8.744

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-05

The current institutional shareholding score of Contineum Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 74.57%, representing a quarter-over-quarter decrease of 1.41%. The largest institutional shareholder is The Vanguard, holding a total of 1.27M shares, representing 4.17% of shares outstanding, with 0.55% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

2.12M

Johnson & Johnson Innovation-JJDC, Inc.

1.98M

Franklin Advisers, Inc.

1.66M

-2.55%

Suvretta Capital Management, LLC

1.72M

The Vanguard Group, Inc.

Star Investors

964.23K

+29.60%

Balyasny Asset Management LP

951.32K

Fidelity Management & Research Company LLC

814.87K

-3.35%

Sectoral Asset Management Inc.

800.79K

Perceptive Advisors LLC

714.59K

+2.16%

HHLR Advisors, Ltd.

669.34K

Risk Assessment

Currency: USD Updated: 2026-02-05

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Contineum Therapeutics Inc is 3.43, ranking 144 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.